The combination of PD1-IL2v and anti-PD-L1 can destroy the resistance of cancer to immunotherapy

Immunotherapy is a method of treating cancer by reprogramming the immune system of patients to attack their tumors. This cutting-edge treatment has had a significant impact on the treatment of cancer patients, and there have been cases of long-term remission.   However, many patients either do not respond to immunotherapy, or even if they do, the effect is temporary, which highlights how important it is for us to better understand…

Read More >>

Interpretation of the Recent PD-1 Research Progress (Part II)

Immunotherapy with oncolytic virus combined with PD-1 inhibitor

Continued   6. Nature’s New Discovery: Another Unidentified Anti-cancer Approach of PD-1 / PD-L1 Antibodies doi: 10.1038/nature22396.   On May 17, Nature published an online article titled “PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity”, revealing the immune checkpoint inhibitors represented by the PD-1 / PD-L1 antibody can fight cancer in a completely different way.   Dr. Irving Weissman, a professor of pathology and developmental biology at Stanford…

Read More >>

Interpretation of the Recent PD-1 Research Progress

PD-1 (programmed cell death protein 1), the programmed death receptor 1, is an important immunosuppressive molecule. Immunomodulation which targets PD-1 is of great importance to anti-tumor, anti-infective, anti-autoimmune diseases, and organ transplant survival. In recent years, scientists have made a number of achievements in the field of PD-1 research. We will share the relevant research here.   1.Science: Scientists confirm that intestinal microbes affect PD-1 / L1 antibody treatment for…

Read More >>